Prosecution Insights
Last updated: November 04, 2026
Application No. 18/430,682

PREPARATION METHOD AND APPLICATION METHOD OF INJECTABLE PLA MICROSPHERES

Final Rejection §112
Filed
Feb 02, 2024
Priority
Jun 07, 2023 — CN 2023106697668
Examiner
SHOMER, ISAAC
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenzhen Esun Industrial Co. Ltd.
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
1m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
757 granted / 1200 resolved
+3.1% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
61 currently pending
Career history
1263
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
45.8%
+5.8% vs TC avg
§102
11.5%
-28.5% vs TC avg
§112
25.9%
-14.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1200 resolved cases

Office Action

§112
DETAILED ACTION Applicants’ arguments, filed 25 August 2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 112(b) – Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the phrase “spray solution.” This phrase is unclear for at least the following reasons. Consistent with the well-established axiom in patent law that a patentee or applicant is free to be his or her own lexicographer, a patentee or applicant may use terms in a manner contrary to or inconsistent with one or more of their ordinary meanings if the written description clearly redefines the terms. With that being said, until the meaning of a term or phrase used in a claim is clear, a rejection under 35 U.S.C. 112(b) is appropriate. See MPEP 2173.05(a)(III). With that being said, in this case, it is unclear if the term “solution” is being used in accordance with its ordinary meaning or whether the term “solution” has been redefined by applicant. The ordinary meaning of the term “solution” is a homogeneous, single-phase mixture in which a solute is mixed in with a solvent. The skilled artisan would have understood an emulsion to have been other than a solution because an emulsion is a heterogeneous, multi-phase mixture of phases that are not miscible. In the case of claim 1, it is unclear whether the term “solution” is being used in accordance with its ordinary meaning or whether the term “solution” has been redefined to include an emulsion. The amendments to claim 1 made in applicant’s response on 25 August 2026 fail to clarify this issue. This is because it is unclear if the spray solution is either a homogenous liquid composition that would ordinarily have been considered to have been a solution by one of ordinary skill in the art; an emulsion; or a mixture of oil and aqueous phase that cannot be considered an emulsion. This rejection does not apply to claim 12 and claims dependent thereon. This is because, in the case of claim 12, it appears that the term “solution” has been redefined within the claim to include an emulsion. An applicant is entitled to be their own lexicographer and may rebut the presumption that claim terms are to be given their ordinary and customary meaning by clearly setting forth a definition of the term that is different from its ordinary and customary meaning(s) in the specification at the relevant time. See MPEP 2111.01(IV)(A). In the case of claim 12, it appears that applicant has redefined the term “solution” to include emulsions within the claim scope. For the purposes of examination under prior art, the examiner will proceed with the understanding that an emulsion is within the scope of the claim term “solution.” Response to Arguments Regarding Indefiniteness Rejection In applicant’s response on 25 August 2026 (hereafter referred to as applicant’s response), page 6, applicant has taken the following position. PNG media_image1.png 102 680 media_image1.png Greyscale This is not persuasive because it still remains unclear as to whether the “spray solution” is a mixture of phases that is an emulsion or a mixture of phases that is not an emulsion. The examiner has included proposed amendments at the end of the office action that would address this issue. Claim Interpretation The examiner also notes here that claim 1 does not appear to require an active agent. With that being said, in view of the claim language “comprising”, an active agent does not actually appear to be excluded by claim 1. The transitional term "comprising", which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03(I). This analysis is not intended to apply to claim 12 or claims dependent thereon. Claim 1 has been amended to require the following: PNG media_image2.png 164 680 media_image2.png Greyscale The examiner understands this newly added limitation to require all of the above-indicated process conditions. As such, a process utilizing an air inlet temperature of 160°C but an air outlet temperature of e.g. 40°C would not be within the claim scope. This is because in such a hypothetical process, the air outlet temperature of the hypothetical process differs from that required by the claimed invention. Claimed Invention Appears Not Useful for Protein/Peptide Drug Delivery Based upon the examiner’s review of the instant claims and specification, it is the examiner’s best understanding that the product made by the claimed method would not appear to be useful for the purpose intended by the instant specification. The examiner presents the following arguments in support of this position. Specification Potentially Indicates Invention is Useful for Protein/Peptide Delivery: As an initial matter, the examiner notes that a review of the instant specification may indicate the that the invention is intended to deliver protein and peptide drugs. See the instant specification on page 2, relevant text reproduced below with annotation by the examiner. PNG media_image3.png 200 790 media_image3.png Greyscale As such, it appears that the instant specification indicates that polylactic acid (PLA) microspheres have been used for the delivery of peptides and proteins. The specification appears to indicate that the instantly claimed invention is to be used for delivery of peptides and proteins. (In contrast, the above-cited portion of the specification may also be interpreted here as disclosing that PLA microspheres have in the past as a carrier for peptide and protein drugs even if that is not their intended purpose in the instant invention. Regardless, the examiner will proceed in this analysis with the assumption that the specification is disclosing that PLA microspheres in the instant invention or being made by the instantly claimed method are being used for protein or peptide drug delivery). Instant Claims do not Recite Protein or Peptide: A review of the instant claims appears to indicate that the claims do not recite a protein or peptide as an active agent to be delivered. Said protein or peptide does not appear to be recited as an optional ingredient or in a dependent claim, let alone in an independent claim. The examiner notes that the instant claims recite macromolecular substances. See e.g. instant claim 6, which is reproduced below with annotation by the examiner. PNG media_image4.png 172 844 media_image4.png Greyscale As such, the instant claims recite macromolecular substances, one of which can be whey protein. However, looking to the specification, it appears that the recited macromolecular substances are intended as excipients. See the instant specification on pages 10-11, paragraph 0115. See relevant text reproduced below from page 11 of the instant specification. PNG media_image5.png 214 794 media_image5.png Greyscale This would appear to indicate that the purpose of the macromolecular substances is as an excipient to affect degradation rate rather than as an active agent or model active agent. As such, none of the claims recite a protein or peptide intended as an active agent such as a therapeutic agent, diagnostic agent, or a model therapeutic agent. With that being said, in view of the claim language “comprising”, an active agent does not actually appear to be excluded by claim 1. The transitional term "comprising", which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See MPEP 2111.03(I). Prior Art Indicates that Double Emulsion is Needed to Deliver Protein/Peptide Drugs with PLA Microsphere: The examiner’s review of the prior art indicates that PLA microspheres have been successfully used to deliver protein and peptide drugs. In support of this position, the examiner cites Iqbal et al. (International Journal of Pharmaceutics 496 (2015), pages 173–190). Iqbal et al. (hereafter referred to as Iqbal) is a review article drawn to double emulsions for delivery of protein and peptide drugs, as of Iqbal, page 173, title and abstract. Iqbal cites a variety of references indicating successful formation of PLA microspheres. See the following examples reproduced below from page 176 of Iqbal. PNG media_image6.png 304 1210 media_image6.png Greyscale With that being said, the examples of Iqbal are all drawn to water-in-oil-in-water (w/o/w) double emulsions. These entail an inner water phase emulsified into an oil phase to form a water-in-oil primary emulsion, which is then emulsified into a secondary water phase to form a water-in-oil-in-water emulsion. As such, the primary water phase is present in the smallest volume, the oil phase is present in an intermediate volume, and the outer water phase is present in the largest volume. The method of loading with a double emulsion appears to be critical to successful encapsulation of hydrophilic substances. In support of this position, see the following text reproduced from Iqbal, page 173, abstract. PNG media_image7.png 160 1028 media_image7.png Greyscale Also see text reproduced below from page 174, right column of Iqbal. PNG media_image8.png 592 728 media_image8.png Greyscale It is the examiner’s understanding that the majority of proteins and peptides are generally hydrophilic molecules. This is because proteins and peptides are made from amino acids, which are polymerized together to include amide functional groups having a carbonyl oxygen that engages in hydrogen bonding with hydrogen atoms from water molecules. Additionally, the majority of amino acids have hydrophilic side chains. Although some proteins and peptides can include hydrophobic regions, often intended as transmembrane regions, it is still the case that the skilled artisan would have understood proteins and peptides to have been generally hydrophilic. As such, for encapsulation of proteins into PLA microspheres, the skilled artisan would have had a reasonable expectation that the double emulsion technique would have been successful in encapsulating proteins and peptides but would not have had a reasonable expectation that the single emulsion technique would have been successful in encapsulating proteins and peptides. Further in support of this position, the examiner notes Lassalle et al. (Macromolecular Bioscience, Vol. 7, 2007, pages 767-783), which is drawn to the formation of PLA microparticles. Lassalle appears to provide a similar teaching as of page 776, right column, top paragraph, relevant text reproduced below. PNG media_image9.png 140 564 media_image9.png Greyscale As such, the teachings of Lassalle appear to be similar to those of Iqbal. Instant Claims Do Not Recite Double Emulsion: Looking at the instant claims, it does not appear that the instant claims recite a double emulsion. In fact, instant claim 12 appears to be specifically drawn to a single emulsion. See the following text reproduced below. PNG media_image10.png 128 840 media_image10.png Greyscale The above-reproduced text appears to indicate a single oil phase and a single aqueous phase. This appears to be a single emulsion rather than a double emulsion. With that being said, the examiner will proceed in examination with the understanding that claim 1 does not exclude a double emulsion. See the section above entitled “Claim Interpretation.” Examples in Specification Do Not Disclose Double Emulsion: Additionally, the examiner reviewed the examples in the instant specification and noted that the examples do not appear to be drawn to double emulsions. See e.g. embodiment 3 on page 6 of the specification, which is reproduced below. PNG media_image11.png 582 812 media_image11.png Greyscale This example does not include an internal water phase separate from an internal oil phase and therefore does not appear to be drawn to a double emulsion. Specification Does Disclose Albumin Addition After Particle Formation However This is Not Recited by Claims: The instant specification does appear to disclose addition of bovine serum albumin (BSA) to an already-formed particle. See the instant specification on pages 12-14, Experimental Example 3, wherein text is reproduced in part below. PNG media_image12.png 374 786 media_image12.png Greyscale Later data on page 13 of the specification indicates that BSA does successfully adsorb to the particles formed by the recited method. With that being said, based upon the above-reproduced text, it is unclear if Experimental Example 3 of the instant specification is intended to be drawn to loading of BSA for drug delivery, or is intended to model the effects of the particle after in vivo administration with BSA in the experiment acting as a model for blood plasma or another naturally occurring substance in the body. As such, given this lack of clarity, it is unclear as to whether the specification actually discloses successful loading of a protein after formation of the particle. Additionally, this feature is not actually recited by the instant claims. No Rejection for Lack of Enablement for This Reason: The examiner notes that according to MPEP 2164.08(c), a feature which is taught as critical in a specification and is not recited in the claims should result in a rejection of such claim under the enablement provision section of 35 U.S.C. 112. With that being said, the presence of a hydrophilic drug does not actually appear to be critical because the description in the specification on page 1, paragraph 0004 appears to indicate that particles lacking drugs are useful for medical cosmetology and as dermal fillers. As such, the instant claims are not rejected for lacking enablement. Relevant Prior Art – No Rejection As relevant prior art, the examiner cites Panda et al. (US 2013/0259948 A1), over which the instant claims were previously rejection in the office action mailed on 23 June 2026. Panda et al. (hereafter referred to as Panda) is drawn to spray-dried powder formulations for vaccines, as of Panda, title and abstract. Panda teaches the following in one embodiment, as of Panda, pages 4-5, Example 1, partially reproduced below. PNG media_image13.png 436 404 media_image13.png Greyscale PNG media_image14.png 122 458 media_image14.png Greyscale Figure 1 is cited in the above-reproduced text and is reproduced below. PNG media_image15.png 612 728 media_image15.png Greyscale Also as relevant prior art, the examiner cites Lassalle et al. (Macromolecular Bioscience, Vol. 7, 2007, pages 767-783), over which the instant claims were previously rejected in the office action mailed on 23 June 2026. Lassalle et al. (hereafter referred to as Lassalle) is drawn to preparation of microparticles and nanoparticles made from poly(lactic acid), which Lassalle abbreviates as PLA, as of Lassalle, page 767, title and abstract. Lassalle teaches the following method on page 769, right column, bottom paragraph, relevant text reproduced below. PNG media_image16.png 244 552 media_image16.png Greyscale Neither Panda, Lassalle, nor their combination read on the claimed requirements. This is because instant claims 1 and 12 require the use of compressed air with a pressure higher than atmospheric pressure, as the minimum pressure recited by claim 9 is 0.3 MPa whereas atmospheric pressure is about 0.1 MPa. This is not taught by either Panda or Lassalle. Also, the required inlet and outlet temperatures are not taught by the prior art. If, purely en arguendo, the skilled artisan would have been motivated to have combined the teachings of Panda and Lassalle, the skilled artisan would not have used an inlet temperature as high as 160°C, as required by the instant claims. This is because the combination of Panda and Lassalle is drawn to administration of a protein as an active agent; this is done by using a double emulsion. The skilled artisan would have been aware that proteins denature at high temperatures, and the skilled artisan would have expected a temperature of 160°C to have been a sufficiently high temperature to have denatured protein payloads. See e.g. Liu et al. (Foods, Vol. 11 Issue 664, 2022, pages 1-14), which includes an analysis of protein denaturation during the process of cooking poultry. Liu teaches the following on the bottom of page 8, relevant text reproduced below. PNG media_image17.png 250 952 media_image17.png Greyscale The above-reproduced text indicates that the proteins measured by Liu denature at temperatures between 55°C and 78°C. The claimed inlet temperature of 160°C is well above the threshold taught by Liu for denaturing of proteins. Therefore, the skilled artisan would have understood that the recited inlet temperature would have been sufficient to have caused protein denaturation. Further in support of this position, the examiner cites Baras et al. (International Journal of Pharmaceutics, Vol. 200, 2000, pages 133-145). Baras et al. (hereafter referred to as Baras) is drawn to spray dried poly(DL-lactide) microparticles comprising antigen, as of Baras, page 133, title and abstract. The antigen used by Baras is the model antigen BSA (bovine serum albumin), as of the abstract of Baras, which is a protein. Baras tests the following inlet and outlet temperatures, as of page 137, Table 1, reproduced below. PNG media_image18.png 280 1278 media_image18.png Greyscale Baras does appear to consider the idea that a high inlet temperature could potentially result in the degradation of antigen, as of Baras, page 143, right column, relevant text reproduced below. PNG media_image19.png 236 480 media_image19.png Greyscale These inlet temperatures (e.g. 44-62°C) tested by Baras are much lower than the inlet temperatures recited by the instant claims (160°C). This would appear to support the position taken by the examiner above that the skilled artisan would not have used a 160°C inlet temperature in a method of encapsulating a protein or peptide active agent. As such, the skilled artisan would not have been motivated to have increased inlet temperature to 160°C for fear that the protein to be delivered would have been denatured at this temperature. Because the instantly claimed invention does not appear to be used for protein delivery, an inlet temperature as high as 160°C can be used because there is no worry that proteins will denature since proteins do not appear to be loaded delivered by the instantly claimed method. Additionally, Panda, Lassalle, and/or their combination do not render claim 12 obvious. This is because claim 12 appears to be drawn to spray drying of a single oil in water emulsion rather than a double emulsion that is a water-in-oil-in-water emulsion. The skilled artisan would not have been motivated to have modified Panda to have been a single oil-in-water emulsion rather than a double emulsion. This is because Panda is drawn to delivery of a hydrophilic vaccine. The skilled artisan would have expected an oil-in-water emulsion to have been wholly unsuitable for delivery of a hydrophilic vaccine. Allowable Subject Matter Claims 12-20 appear to be allowable. Claims 12-20 are not subject to a prior art rejection for the reasons set forth above. Claims 12-20 are also not subject to a rejection under 35 U.S.C. 112(b). This is because, in the case of claim 12, it appears that the term “solution” has been redefined within the claim to include an emulsion. An applicant is entitled to be their own lexicographer and may rebut the presumption that claim terms are to be given their ordinary and customary meaning by clearly setting forth a definition of the term that is different from its ordinary and customary meaning(s) in the specification at the relevant time. See MPEP 2111.01(IV)(A). In the case of claim 12, it appears that applicant has redefined the term “solution” to include emulsions within the claim scope. The examiner has set forth a proposed examiner’s amendment on the next page which includes a suggestion of how to amend all of the claims to be in condition for allowance. This proposed examiner’s amendment includes a suggestion for an amendment to claim 12. The suggestion is not required because claim 12 is already in condition for allowance, but the suggestion would cause the language of claim 12 to moreso use terms in accordance with their ordinary and customary definition in the English language. Proposed Examiner’s Amendment The examiner has proposed the following amendments in order to overcome the previously applied rejections. Claim 1 (Proposed Amendment): A preparation method of injectable polylactic acid (PLA) microspheres, comprising: S01, preparing a [[ ]] mixture of an oil phase and aqueous phase wherein the [[ ]] oil phase comprises an organic solvent and PLA, and [[ ]] the weight ratio of the oil phase and the aqueous phase is 1-10 : 1-10; S02, performing emulsification on the [[ ]] mixture of phases to obtain an [[ ]] liquid emulsion; and S03, drying the [[ ]] liquid emulsion to obtain the injectable PLA microspheres; wherein process conditions of the drying the [[ ]] liquid emulsion comprise: an input rate of the [[ ]] liquid emulsion being in a range of 4-20 milliliters per minute (mL/min), a pressure of compressed air being in a range of 0.3-0.5 megapascals (MPa), an air inlet temperature being 160 Celsius degrees (°C), an air outlet temperature being 80°C, and carrier gas being inert gas or air; and S04, collecting the PLA microspheres [[ ]] in a cyclone separator, and [[ ]] further drying under reduced pressure below 60°C after collecting in the cyclone separator. Claim 2 (Proposed Amendment): The preparation method of the injectable PLA microspheres as claimed in claim 1, wherein in the step S01, [[ ]] the aqueous phase comprises a surfactant, macromolecular substances and deionized water. Claim 3 – No Amendment proposed to claim 3. Claim 4 – No Amendment proposed to claim 4; however, applicant may amend this claim to depend from claim 1 if applicant desires to do so. Claim 5 – No Amendment proposed to claim 5. Claim 6 – No Amendment proposed to claim 6. Claim 7 – No Amendment proposed to claim 7. Claim 8 (Proposed Amendment): The preparation method of the injectable PLA microspheres as claimed in claim 1, wherein in the step S02, a temperature of the emulsification [[ ]] is 50°C, wherein a homogenizer is used to achieve emulsification and a rotational speed of [[ ]] the homogenizer is in a range of 3000-5000 revolutions per minute (rpm), and a time of the emulsification [[ ]] is in a range of 5-10 minutes (min). Claim 9 – already cancelled. Claims 10-11 – Proposed Cancellation: The examiner proposes cancelling these claims because they do not appear to be in condition for rejoinder. As an initial matter, claim 10 recites “[A]n application method of the injectable PLA microspheres as claimed in claim 1.” This appears to incorrectly characterize claim 1 because claim 1 is drawn to a method of making injectable PLA microspheres rather than the PLA microspheres themselves and thereby introduce an additional issue under 35 U.S.C. 112(b). Although the above claimed method is indicated as allowable, that should not be construed as an indication that the PLA microspheres made by the method of claim 1, if claimed, would be allowable. Additionally, were claims 10-11 to be rejoined, it is unclear to what extent the process steps of claim 1 would limit the claim scope of claims 10-11 and it is therefore unclear whether claims 10-11 should be examined in view of the product-by-process guidelines set forth in MPEP 2113. As such, to expedite allowance, the examiner proposes cancelling these claims. The examiner has set forth a proposed amendment for claim 12; this amendment does not appear to be required to place the application in condition for allowance but would appear to render the claim language such that claim terms are being interpreted in accordance with their ordinary definitions. Claim 12 (Amendment Suggested but not Required): A preparation method of injectable PLA microspheres, comprising: preparing a [[ ]] mixture of an oil phase and an aqueous phase, [[ ]] wherein the weight ratio of the oil phase and the aqueous phase is 1-10 : 1-10; [[ ]] wherein the oil phase comprises PLA and an organic solvent, and wherein the aqueous phase comprises a surfactant, macromolecular substances and deionized water; performing emulsification using a homogenizer on the [[ ]] mixture of the oil and aqueous phases to obtain [[ ]] a liquid emulsion; wherein a temperature of the emulsification [[ ]] is 50°C, a rotational speed of [[ ]] the homogenizer is in a range of 3000-5000 rpm, and a time of the emulsification [[ ]] is in a range of 5-10 min; and drying the [[ ]] liquid emulsion to obtain the injectable PLA microspheres; wherein an input rate of the [[ ]] liquid emulsion is in a range of 4-20 mL/min, a pressure of compressed air is in a range of 0.3-0.5 MPa, an air inlet temperature is 160°C, an air outlet temperature is 80°C, and carrier gas is inert gas or air. Claim 13 – No amendment proposed to claim 13. Claim 14 – No amendment proposed to claim 14. Claim 15 – No amendment proposed to claim 15. Claim 16 – No amendment is proposed to claim 16. Claim 17 – No amendment is proposed to claim 17. Claim 18 – No amendment is proposed to claim 18. Claim 19 – No amendment is proposed to claim 19. Claim 20 – No amendment is proposed to claim 20. Conclusion Less than all claims are in condition for allowance at this time. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ISAAC SHOMER whose telephone number is (571)270-7671. The examiner can normally be reached 7:30 AM to 5:00 PM Monday Through Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at (571)272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ISAAC . SHOMER Primary Examiner Art Unit 1612 /ISAAC SHOMER/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Feb 02, 2024
Application Filed
Jun 23, 2026
Non-Final Rejection mailed — §112
Aug 25, 2026
Response Filed
Oct 07, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778875
COSMETIC COMPOSITION COMPRISING A CATIONIC ASSOCIATIVE POLYMER, A CARBOXYLIC ANIONIC SURFACTANT, OPTIONALLY A NONIONIC SURFACTANT AND AN AMPHOTERIC OR ZWITTERIONIC SURFACTANT
4y 4m to grant Granted Nov 03, 2026
Patent 12779011
CYCLOSPORINE FORMULATIONS FOR USE IN THE PREVENTION OR TREATMENT OF PULMONARY CHRONIC GRAFT REJECTION
3y 3m to grant Granted Nov 03, 2026
Patent 12766100
In Vivo Targeting of Extracellular Vesicles
3y 11m to grant Granted Oct 20, 2026
Patent 12766109
SUGAR-COATED MELANIN NANOPARTICLES AND METHOD FOR TARGETING METASTATIC CANCER CELLS
3y 7m to grant Granted Oct 20, 2026
Patent 12766203
METHOD FOR PRODUCING RADIOACTIVE ZIRCONIUM COMPLEX
3y 6m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
93%
With Interview (+30.3%)
2y 11m (~1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1200 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month